Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118:3272–87.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J Eur Heart J. 2016;37:2129–200.

Article  PubMed  Google Scholar 

Ringel MS, Shah NA, Baedeker M, Lim CT, Lamichhane A, Schulze U. Occlusion in the flow of new drugs for cardiovascular disease. Clin Pharmacol Ther. 2017;102:246–53.

Article  CAS  PubMed  Google Scholar 

Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19:79–84.

Google Scholar 

Kort E, Jovinge S. Drug repurposing: claiming the full benefit from drug development. Curr Cardiol Rep. 2021;23:62.

Abdelsayed M, Kort EJ, Jovinge S, Mercola M. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat Rev Cardiol. 2022;19:751–64.

Chaffey L, Roberti A, Greaves DR. Drug repurposing in cardiovascular inflammation: successes, failures, and future opportunities. Front Pharmacol. 2022;13:1046406.

Gelosa P, Castiglioni L, Camera M, Sironi L. Repurposing of drugs approved for cardiovascular diseases: opportunity or mirage? Biochem Pharmacol. 2020;177:113895.

Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.

Article  CAS  PubMed  Google Scholar 

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.

Article  CAS  PubMed  Google Scholar 

Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752–62.

Article  CAS  PubMed  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61.

Article  CAS  PubMed  Google Scholar 

Onódi Z, Koch S, Rubinstein J, Ferdinandy P, Varga Z V. Drug repurposing for cardiovascular diseases: new targets and indications for probenecid. Br J Pharmacol. 2023;180:685–700.

Tual-Chalot S, Stellos K. Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure. Eur Heart J. 2021;42:3783–5.

March-Vila E, Pinzi L, Sturm N, Tinivella A, Engkvist O, Chen H, et al. On the integration of in silico drug design methods for drug repurposing. Front Pharmacol. 2017;8:298.

Article  PubMed  PubMed Central  Google Scholar 

Iwata H, Sawada R, Mizutani S, Yamanishi Y. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data. J Chem Inf Model. 2015;55:446–59.

Article  CAS  PubMed  Google Scholar 

Fiedler LR, Chapman K, Xie M, Maifoshie E, Jenkins M, Golforoush PA, et al. MAP4K4 Inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo. Cell Stem Cell. 2019;24:579–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKeithan WL, Feyen DAM, Bruyneel AAN, Okolotowicz KJ, Ryan DA, Sampson KJ, et al. Reengineering an antiarrhythmic drug using patient hiPSC cardiomyocytes to improve therapeutic potential and reduce toxicity. Cell Stem Cell. 2020;27:813–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pott A, Rottbauer W, Just S. Streamlining drug discovery assays for cardiovascular disease using zebrafish. Expert Opin Drug Discov. 2020;15:27–37.

Article  CAS  PubMed  Google Scholar 

Hassan S, Lone MA. Editorial: Genetic disorders and rare diseases: in vitro models for preclinical pharmacological studies and translation. Front Pharmacol. Frontiers; 2023;14:1346648.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.

Article  CAS  PubMed  Google Scholar 

Miller AM. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22.

Article  CAS  Google Scholar 

Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol Nature Publishing Group. 2010;10:103–10.

Article  CAS  Google Scholar 

Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684–91.

Article  CAS  PubMed  Google Scholar 

Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. The Rockefeller University Press. 2008;205:339–46.

Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res Europe PMC Funders. 2010;107:650–8.

Article  CAS  Google Scholar 

Shao D, Perros F, Humbert M, Caramori G, Price L, Addcock I, et al. Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension? Thorax BMJ Publishing Group Ltd. 2010;65:A70–A70.

Google Scholar 

Shao D, Perros F, Caramori G, Meng C, Dormuller P, Chou P-C, et al. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochem Biophys Res Commun. 2014;451:8–14.

Article  CAS  PubMed  Google Scholar 

Thanikachalam PV, Ramamurthy S, Mallapu P, Varma SR, Narayanan J, Abourehab MA, et al. Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases. Cytokine Growth Factor Rev. 2023;71-72:94–104.

Veeraveedu PT, Sanada S, Okuda K, Fu HY, Matsuzaki T, Araki R, et al. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochem Pharmacol. Elsevier Inc. 2017;138:73–8.

Firouzabadi N, Dashti M, Dehshahri A, Bahramali E. Biomarkers of IL-33 and SST2 and lack of association with carvedilol therapy in heart failure. Clin Pharmacol Adv Appl. 2020;12:53–8.

CAS  Google Scholar 

Xia J, Qu Y, Yin C, Xu D. Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction. Cardiol J. 2017;24:188–94.

Article  PubMed  Google Scholar 

Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta - Mol Basis Dis. 2013;1832:2442–50.

Article  CAS  Google Scholar 

Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL. Soluble concentrations of the interleukin receptor family member ST2 and β-Blocker therapy in chronic heart failure. Circ Hear Fail. 2013;6:1206–13.

Article  CAS  Google Scholar 

Huang WP, Zheng X, He L, Su X, Liu CW, Wu MX. Role of soluble ST2 levels and beta-blockers dosage on cardiovascular events of patients with unselected ST-segment elevation myocardial infarction. Chin Med J (Engl). 2018;131:1282–8.

Article  CAS  PubMed  Google Scholar 

Lax A, Sanchez-Mas J, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Hear Fail. 2015;3:50–8.

Article  Google Scholar 

Ren N, Jiang H, Chen S, Du J, Li W, Huo X, et al. Aldosterone receptor antagonist mitigates diastolic heart failure through inhibition of interleukin-33/ST2 signaling pathway. Acta Medica Mediterr. 2021;37:2439–47.

Google Scholar 

Chen B, Geng J, Gao S-X, Yue W-W, Liu Q. Eplerenone modulates interleukin-33/sST2 signaling and IL-1β in left ventricular systolic dysfunction after acute myocardial infarction. J Interf Cytokine Res. 2018;38:137–44.

Article  CAS  Google Scholar